Fact-checked by Grok 2 weeks ago

Cachexia

Cachexia is a multifactorial metabolic syndrome associated with underlying chronic diseases, characterized by involuntary loss of skeletal muscle mass (with or without concurrent loss of fat mass), systemic inflammation, negative protein and energy balance, and progressive functional impairment.^[1]^[2]^[3] This condition most commonly manifests in patients with advanced cancer, where it affects approximately 33% of cases overall, though prevalence varies by cancer type and stage; it also occurs in other chronic illnesses, including heart failure (prevalence around 31%), chronic obstructive pulmonary disease, chronic kidney disease, and rheumatoid arthritis.^[4]^[5]^[6] Cachexia contributes substantially to morbidity and mortality, as it exacerbates disease progression, reduces treatment tolerance, and shortens survival by disrupting metabolic homeostasis and physical function.^[7]^[8] The pathophysiology of cachexia involves a dysregulated interplay of inflammatory cytokines (such as tumor necrosis factor-alpha and interleukin-6), heightened muscle protein breakdown, suppressed appetite (anorexia), and altered energy expenditure, leading to a futile cycle of tissue wasting despite potential nutritional intake.^[2]^[7] These mechanisms are triggered by the underlying disease, resulting in adipose tissue inflammation and lipolysis alongside skeletal muscle atrophy.^[3]^[8] Clinically, cachexia presents with symptoms including profound fatigue, weakness, reduced muscle strength, anorexia, and unintended weight loss exceeding 5% of body weight over six months (or lower thresholds in combination with low body mass index), often accompanied by biochemical signs of inflammation such as elevated C-reactive protein levels.^[7]^[1]^[9] It markedly impairs quality of life, limits physical activity, and increases susceptibility to complications like infections and falls.^[7]^[8] Diagnosis relies on standardized criteria, such as those from the Fearon framework, which emphasize weight loss severity, muscle depletion, and inflammatory markers, while excluding simple starvation or dehydration.^[3]^[9] There is no single curative treatment, but management follows a multimodal approach: addressing the primary disease, providing nutritional support (e.g., high-calorie supplements), incorporating resistance exercise to preserve muscle, and using pharmacotherapies like progestins (e.g., megestrol acetate) for appetite stimulation, anti-inflammatory agents, or emerging anabolic therapies to counteract catabolism.^[10]^[3]^[11] Early screening and intervention are critical to mitigate its progression and improve outcomes.^[12]^[10]

Definition and Characteristics

Core Definition

Cachexia is a multifactorial syndrome associated with underlying chronic illness, characterized by the involuntary loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional interventions and leads to progressive functional impairment, including weakness and fatigue.^[1] This condition manifests in various chronic diseases, such as cancer, chronic heart failure, chronic obstructive pulmonary disease, and chronic kidney disease, contributing to poor clinical outcomes.^[1] Key clinical features of cachexia include involuntary weight loss greater than 5% over 6 months (or more than 2% over 6 months in individuals with a body mass index below 20 kg/m²), anorexia, early satiety, anemia, fatigue, and systemic inflammation, distinguishing it from simple starvation or caloric deprivation alone.^[13] These hallmarks reflect a complex interplay of metabolic dysregulation rather than mere nutritional deficiency, often accompanied by biochemical markers like elevated C-reactive protein levels indicating inflammation.^[1] Cachexia significantly impairs quality of life through diminished physical function, increased symptom burden, and psychological distress, while also being a strong predictor of adverse prognosis.^[14] In advanced stages, particularly in cancer patients, it affects up to 80% of cases and contributes to 20–30% of cancer-related deaths, underscoring its role as a major contributor to mortality in chronic illnesses.^[15] At a basic level, the pathophysiology involves cytokine-mediated muscle wasting, driven by inflammatory responses from the underlying disease.^[16]

Distinctions from Malnutrition and Sarcopenia

Cachexia differs from malnutrition in that it is driven by systemic inflammation and hypermetabolism, leading to ongoing tissue wasting even when caloric intake is adequate or increased, whereas malnutrition stems primarily from insufficient nutrient intake and generally reverses with appropriate refeeding.^[17] In cachexia, particularly in cancer patients, elevated inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 contribute to a catabolic state that resists nutritional interventions alone, unlike the adaptive metabolic response in starvation-based malnutrition where the body conserves energy.^[18] This refractory nature underscores cachexia's multifactorial etiology beyond mere caloric deficit.^[19] In contrast to sarcopenia, which represents a progressive, age-related decline in skeletal muscle mass and function without an underlying chronic disease, cachexia is a rapid-onset syndrome tied to specific illnesses like cancer or heart failure, encompassing not only muscle loss but also adipose tissue depletion and broader systemic metabolic disruptions.^[20] While both conditions involve reduced muscle quantity and quality, sarcopenia progresses slowly over years due to factors like hormonal changes and inactivity in older adults, whereas cachexia accelerates over weeks to months, often with anorexia and fatigue as prominent features.^[21] The overlap in muscle wasting can complicate differentiation, but cachexia's inclusion of fat mass loss and inflammatory markers sets it apart.^[22] Diagnostically, cachexia requires confirmation of an underlying disease alongside involuntary weight loss exceeding 5% over six months (or less with inflammation), emphasizing clinical history and biomarkers like C-reactive protein, whereas sarcopenia diagnosis centers on individuals aged 65 or older, relying on measurements of muscle strength (e.g., handgrip <27 kg for men), mass (via dual-energy X-ray absorptiometry), and performance (e.g., gait speed <0.8 m/s).^[18] This disease-centric approach for cachexia versus the age- and function-focused criteria for sarcopenia helps prevent misdiagnosis, guiding targeted interventions such as anti-inflammatory therapies for cachexia rather than exercise for sarcopenia.^[23] For instance, cancer cachexia in a middle-aged patient presents as swift, multifactorial wasting unresponsive to diet, distinct from sarcopenia in a disease-free elderly individual where muscle loss is gradual and primarily affects mobility.^[24]

Etiology

Underlying Diseases

Cachexia is primarily precipitated by a range of chronic and progressive diseases that trigger systemic metabolic dysregulation and tissue wasting. The most common underlying conditions include malignancies, cardiovascular disorders, respiratory diseases, renal failure, autoimmune conditions, chronic infections, and liver cirrhosis. These diseases initiate cachexia through disease-specific mechanisms, such as the release of pro-inflammatory and catabolic factors, leading to involuntary weight loss, muscle atrophy, and fat depletion.^[25] Among malignant diseases, cancer is the leading cause of cachexia, affecting 50-80% of patients in advanced stages. Pancreatic cancer exhibits one of the highest prevalences, impacting over 80% of patients due to tumor-derived factors like cytokines and proteolysis-inducing factor that promote muscle breakdown and appetite suppression. Similarly, lung cancer is associated with cachexia in 50-80% of cases, where tumor-secreted mediators exacerbate systemic inflammation and metabolic shifts. Overall, cancer-related cachexia occurs in 28-57% of patients across various tumor types, highlighting its role as a hallmark of advanced malignancy.^[26]^[27]^[28] Non-malignant conditions also frequently underlie cachexia, particularly in chronic illnesses. Chronic heart failure (CHF) is associated with cachexia in 5-15% of patients overall (up to 30-50% in advanced stages), through mechanisms involving cardiac dysfunction, hypoxia, and elevated inflammatory cytokines that impair nutrient utilization and promote cardiac and skeletal muscle wasting. Chronic obstructive pulmonary disease (COPD) is linked to cachexia in 15-35% of cases, initiated by pulmonary hypoxia, oxidative stress, and chronic inflammation that disrupt energy metabolism and accelerate protein catabolism.^[1]^[25] Chronic kidney disease (CKD) precipitates cachexia in 20-50% of advanced cases, driven by uremic toxins, metabolic acidosis, and inflammation that hinder anabolic processes. Liver cirrhosis contributes to cachexia in 20-40% of patients, involving portal hypertension, malnutrition, and inflammatory signals leading to sarcopenia and muscle wasting. Rheumatoid arthritis contributes in 18-67% of patients, where joint inflammation and autoimmune cytokines like TNF-α systemically induce muscle proteolysis. Chronic infections, such as HIV/AIDS and tuberculosis, are significant triggers; in the era of modern antiretroviral therapy, HIV leads to cachexia in approximately 18% of people with HIV cumulatively (higher in untreated advanced cases) via viral-induced immune activation and malabsorption, while tuberculosis affects around 50% of patients through persistent inflammation, cytokine release, and nutritional deficits that initiate wasting.^[28]^[25]^[29]^[30]

Contributing Factors

Cachexia is exacerbated by several modifiable factors that amplify weight loss and muscle wasting beyond the direct effects of underlying diseases. Poor appetite, often induced by medications, plays a significant role; polypharmacy in older adults leads to side effects such as anorexia, which contributes to malnutrition and reduced caloric intake.^[31] Immobility further worsens the condition by promoting disuse atrophy, creating a vicious cycle where fatigue from cachexia reduces physical activity, thereby accelerating skeletal muscle loss through enhanced proteolysis.^[32] Psychological stress, particularly depression, is prevalent in 10-30% of cancer patients and leads to diminished appetite and physical activity, intensifying cachectic symptoms.^[7] Demographic characteristics increase susceptibility to cachexia in specific contexts. Advanced age, particularly over 65 years, heightens vulnerability due to age-related declines in muscle mass and metabolic function, making older individuals more prone to severe wasting.^[33] In certain cancers, male gender is associated with higher rates of severe muscle loss, occurring in approximately 61% of males compared to 31% of females, potentially linked to differences in hormonal profiles and body composition.^[9] Environmental influences, including inadequate access to care, hinder effective management and exacerbate cachexia progression. Limited availability of specialists and reimbursement for interventions, such as nutritional support, restricts timely screening and treatment, particularly in resource-constrained settings.^[34] Polypharmacy, often resulting from fragmented care, commonly causes nausea and further suppresses appetite, compounding nutritional deficits.^[31] These factors often interact with disease-specific processes; for instance, continued smoking in patients with chronic obstructive pulmonary disease (COPD) significantly worsens cachexia by promoting muscle dysfunction and mitochondrial damage, independent of disease severity.^[35] Addressing such interactions through targeted interventions like smoking cessation can mitigate the amplified wasting observed in COPD-related cachexia.^[35]

Pathophysiology

Inflammatory Mechanisms

Cachexia is characterized by a persistent systemic inflammatory response that drives skeletal muscle wasting through the actions of pro-inflammatory cytokines. Tumor necrosis factor-alpha (TNF-α) plays a central role by binding to its receptors on muscle cells, activating the nuclear factor kappa-B (NF-κB) pathway, which promotes apoptosis and inhibits protein synthesis, leading to muscle atrophy.^[36] Interleukin-6 (IL-6), another key cytokine, signals through the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, enhancing muscle proteolysis and suppressing myogenesis, thereby exacerbating cachectic muscle loss.^[37] Similarly, interleukin-1 beta (IL-1β) contributes by stimulating catabolic processes in skeletal muscle, including the upregulation of degradative enzymes.^[38] These cytokines converge on common downstream pathways, notably the activation of the ubiquitin-proteasome system (UPS), which is responsible for the majority of protein degradation in muscle tissue during cachexia. TNF-α, in particular, induces UPS components such as muscle RING-finger 1 (MuRF1) and muscle atrophy F-box (MAFbx/atrogin-1) via NF-κB signaling, resulting in accelerated breakdown of myofibrillar proteins.^[39] Animal models of cachexia, including tumor-bearing mice, demonstrate that TNF-α overexpression or administration leads to substantial skeletal muscle loss, underscoring its mechanistic importance.^[40] Beyond muscle, inflammation in cachexia triggers systemic effects, including the acute phase response mediated by IL-6, which elevates hepatic production of C-reactive protein and other acute-phase proteins, further perpetuating the catabolic state.^[41] TNF-α and IL-6 also promote lipolysis in adipose tissue and induce insulin resistance by impairing glucose uptake in peripheral tissues, contributing to the overall metabolic derangements observed.^[42] Clinical evidence supports these mechanisms, with elevated circulating levels of TNF-α, IL-6, and IL-1β detected in the majority of cachectic patients across various underlying conditions, such as advanced cancer.^[7]

Metabolic and Hormonal Dysregulations

Cachexia is characterized by profound metabolic shifts that contribute to sustained energy inefficiency and tissue wasting. A hallmark feature is hypermetabolism, defined as an elevated resting energy expenditure (REE) exceeding 110% of predicted values, often increased by 10-20% compared to healthy individuals.^[43]^[44] This hypermetabolism arises from upregulated futile substrate cycles, such as the amplification of the Cori cycle, where glucose is inefficiently converted to lactate in peripheral tissues (including tumors) and then recycled back to glucose in the liver, resulting in net energy loss without productive output.^[44]^[45] These cycles exacerbate the energy deficit, promoting catabolism even in the presence of adequate nutrient intake. Hormonal dysregulations further perpetuate these metabolic alterations, with chronic elevation of cortisol via hypothalamic-pituitary-adrenal axis activation driving glucocorticoid-induced muscle proteolysis.^[46] Cortisol promotes protein breakdown through activation of FOXO transcription factors, which upregulate ubiquitin-proteasome pathways and autophagy in skeletal muscle.^[47] Concurrently, anabolic hormones are diminished; insulin-like growth factor-1 (IGF-1) levels are typically reduced by approximately 50% in cachectic states, impairing muscle protein synthesis and repair.^[48] Ghrelin, an orexigenic hormone, is often dysregulated with elevated circulating levels, yet fails to stimulate appetite effectively due to central resistance, contributing to anorexia and reduced caloric intake.^[49]^[50] To quantify these changes, REE in cachexia can be assessed relative to predictive equations like the Mifflin-St Jeor formula for basal metabolic rate (BMR, often used as a proxy for REE). For males:

\text{BMR (kcal/day)} = 10 \times \text{weight (kg)} + 6.25 \times \text{height (cm)} - 5 \times \text{age (years)} + 5

For females:

\text{BMR (kcal/day)} = 10 \times \text{weight (kg)} + 6.25 \times \text{height (cm)} - 5 \times \text{age (years)} - 161

In cachectic patients, measured REE typically exceeds this predicted value by 10-20%, reflecting the hypermetabolic state adjusted for disease-related factors.^[51]^[52] These metabolic and hormonal imbalances manifest in a preferential loss of skeletal muscle mass, despite concomitant depletion of adipose tissue, leading to a disproportionate impact on lean body composition and functional capacity.^[49]^[3] Inflammatory signals from underlying diseases amplify these dysregulations, sustaining the catabolic milieu.^[53]

Diagnosis

Clinical Criteria and Staging

Cachexia diagnosis relies on standardized clinical criteria that emphasize weight loss in the context of underlying disease and systemic features, moving beyond isolated metrics to capture its multifactorial nature. The 2011 international consensus, led by Fearon and colleagues, defines cancer cachexia as a complex metabolic syndrome characterized by unintentional weight loss greater than 5% over 6 months (in the absence of simple starvation) or greater than 2% if accompanied by a body mass index (BMI) below 20 kg/m², along with reduced muscle mass and at least one additional factor such as anorexia, fatigue, or inflammation.^[54]^[18] This framework incorporates clinical symptoms like decreased food intake and elevated inflammatory markers (e.g., C-reactive protein), ensuring the diagnosis reflects ongoing pathophysiology rather than transient malnutrition. The criteria apply primarily to cancer-associated cachexia but have been adapted for other chronic conditions, highlighting the syndrome's progressive trajectory. Recent modifications as of 2025 propose simpler alternatives for assessing reduced muscle mass, such as handgrip strength (<22 kg males, <16.1 kg females) or neutrophil-to-lymphocyte ratio (≥3.5), to improve clinical applicability.^[55] Earlier definitions of cachexia were less precise, often relying on arbitrary thresholds such as weight loss exceeding 10% of body weight over 6-12 months, without accounting for inflammation or metabolic derangements, which limited their clinical utility and specificity.^[56] These outdated approaches, common before the 2000s, treated cachexia primarily as a starvation-like state and overlooked its distinct inflammatory components, leading to underdiagnosis in early stages.^[57] In contrast, modern criteria prioritize a holistic assessment to facilitate earlier intervention. Staging systems provide a structured way to classify cachexia severity and guide prognosis. The Fearon classification, integrated into the 2011 consensus, delineates three stages: pre-cachexia, marked by subtle weight loss under 5%, anorexia, and early metabolic changes; cachexia, involving symptomatic weight loss over 5% with inflammation and functional decline; and refractory cachexia, an end-stage phase unresponsive to antitumor therapy, with severe weight loss exceeding 15% and life expectancy under 3 months.^[54]^[18] Severity within stages can be further quantified by combining BMI (e.g., <20 kg/m² indicating depletion) with ongoing weight loss rates. Complementary tools like the Cachexia Staging Score (CSS), ranging from 0-12, integrate weight loss, inflammation (e.g., elevated CRP), anorexia, and reduced performance to categorize patients as non-cachectic (0-2), pre-cachectic (3-4), cachectic (5-8), or refractory (9-12).^[58] Clinical assessment incorporates functional evaluations to confirm muscle involvement and severity. Handgrip strength testing, a simple bedside measure, is commonly used; values below age- and sex-specific reference norms (e.g., <27 kg for men, <16 kg for women) signal significant weakness and support cachexia diagnosis when combined with weight loss criteria.^[59] Other functional metrics, such as the 6-minute walk test, may assess overall performance but are secondary to grip strength for routine screening.^[60] These assessments emphasize practical, non-invasive tools to monitor progression without relying solely on anthropometrics.

Laboratory and Imaging Assessments

Laboratory assessments play a crucial role in objectively confirming inflammation, nutritional status, and metabolic derangements associated with cachexia. C-reactive protein (CRP) levels exceeding 10 mg/L serve as a key marker of systemic inflammation, commonly elevated in cachectic patients due to underlying disease processes.^[54] Hypoalbuminemia, with serum albumin below 3.5 g/dL, indicates poor prognosis and reflects hepatic synthesis impairment amid chronic inflammation, frequently observed in cachexia cohorts.^[61] Circulating cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are routinely measured, with elevated levels correlating to muscle catabolism and appetite suppression in cachectic states.^[62] Anemia markers, including hemoglobin concentrations under 12 g/dL, highlight erythropoietic dysfunction linked to inflammatory cytokines, prevalent in up to 80% of advanced cancer patients with cachexia.^[63] Imaging modalities provide quantitative evaluation of body composition, essential for diagnosing and monitoring cachexia beyond clinical symptoms. Dual-energy X-ray absorptiometry (DEXA) assesses lean muscle mass, identifying cachexia when appendicular skeletal muscle index (ASMI) falls below age- and sex-matched norms (e.g., <7.0 kg/m² for males, <5.4 kg/m² for females), offering a non-invasive measure of total body and regional composition.^[64]^[55] Computed tomography (CT) and magnetic resonance imaging (MRI) quantify cross-sectional muscle area at standardized sites, such as the L3 vertebral level, where a reduced psoas muscle index below established thresholds signals sarcopenic cachexia; these techniques are considered gold standards for precision in detecting appendicular and trunk muscle depletion.^[65] Bioelectrical impedance analysis (BIA) estimates fat-free mass and phase angle, providing a portable alternative for tracking extracellular water and muscle quality in resource-limited settings.^[66] These assessments enable tracking of cachexia progression, with CT and MRI capable of detecting 5-10% skeletal muscle loss over three months, facilitating timely intervention alongside clinical criteria.^[64] However, advanced imaging like CT and MRI faces limitations including high costs, limited availability in non-specialized centers, and radiation exposure concerns, restricting routine use in early-stage monitoring.^[67] Laboratory tests, while more accessible, require serial measurements to account for variability influenced by acute-phase responses.^[68]

Management

Nutritional and Exercise Strategies

Nutritional strategies for managing cachexia emphasize increasing energy and protein intake to counteract muscle wasting and metabolic demands. Evidence-based recommendations include targeting 25-30 kcal/kg body weight per day through high-calorie oral nutritional supplements (ONS) with a density of 1.5-2.0 kcal/mL, which help meet elevated requirements in cachectic patients without excessive volume.^[69] Protein-rich diets are advised at 1.2-1.5 g/kg body weight per day to support muscle protein synthesis, often incorporated into frequent small meals or fortified foods.^[70] Additionally, supplementation with omega-3 fatty acids, such as eicosapentaenoic acid (EPA) from fish oil at 2-4 g/day, has shown benefits in reducing inflammation and stabilizing weight by modulating cytokine activity and improving appetite.^[71] Exercise protocols, particularly when combined with nutritional support, play a crucial role in preserving or increasing muscle mass in cachexia. Resistance training is recommended 3 times per week at 60-80% of one-repetition maximum (1RM) load, focusing on major muscle groups to promote hypertrophy and strength gains.^[72] This should be paired with moderate aerobic exercise, such as walking or cycling, to enhance overall function and cardiovascular health, with sessions tailored to patient frailty to ensure safety and adherence. Clinical trials have demonstrated that such combined programs may help preserve or modestly increase lean muscle mass, countering the catabolic effects of the underlying disease.^[73] Randomized controlled trials (RCTs) of multimodal interventions integrating nutrition and exercise report modest weight stabilization or small gains (around 1-2%) in cachectic patients, alongside improvements in quality of life and physical performance, highlighting their synergistic effects.^[74] These approaches form a foundational part of cachexia management, complementing pharmacological options by addressing reversible factors like inactivity and undernutrition. Monitoring progress involves weekly assessments of body weight, muscle strength (e.g., via handgrip dynamometry), and functional capacity to adjust interventions and evaluate efficacy.^[75]

Pharmacological and Emerging Therapies

Megestrol acetate, a synthetic progestin, is commonly used as an appetite stimulant in cachexia management, particularly in cancer patients, at doses ranging from 160 to 800 mg per day. Clinical trials have demonstrated that it can increase body weight by approximately 2-3 kg over several weeks, primarily through fat mass accrual rather than lean tissue preservation.^[75] However, its use is associated with significant risks, including thromboembolism, fluid retention, and adrenal suppression, limiting long-term application.^[75] Corticosteroids, such as dexamethasone at 2-4 mg daily, are recommended for short-term relief in acute cachexia cases to enhance appetite and reduce inflammation. These agents provide symptomatic benefits, including improved energy and food intake, but effects typically wane after 2-3 weeks, and prolonged use risks myopathy, hyperglycemia, and immunosuppression.^[72] Guidelines emphasize their role as a temporary adjunct rather than a standalone therapy.^[75] Emerging pharmacological approaches target cachexia's inflammatory and metabolic pathways. Anti-cytokine agents like tocilizumab, an IL-6 receptor inhibitor, have shown promise in phase II trials for reducing systemic inflammation and improving symptoms in patients with elevated IL-6 levels, such as those with non-small-cell lung cancer cachexia, though larger studies are needed to confirm efficacy.^[76] Anabolic agents, including testosterone derivatives like oxandrolone, aim to promote muscle anabolism; small trials indicate modest gains in lean mass and strength, but androgenic side effects and contraindications in hormone-sensitive cancers restrict their use.^[77] Ghrelin mimetics, such as anamorelin, have advanced further, with phase III ROMANA trials demonstrating 1-2% increases in lean body mass and reductions in anorexia symptoms over 12-16 weeks in advanced cancer patients, alongside improvements in quality of life.^[78] Additionally, ponsegromab, a monoclonal antibody targeting GDF-15, has demonstrated in phase II trials (as of 2024) improvements in weight and physical function, with phase III studies underway as of 2025.^[79] Multimodal therapies integrating pharmacological agents with nutritional support have yielded superior outcomes compared to monotherapy. For instance, combining appetite stimulants or anabolic drugs with high-calorie supplements has been associated with greater improvements in weight stabilization and functional status in cancer cachexia cohorts, highlighting the synergy in addressing multifactorial drivers.^[80] Despite these advances, pharmacological treatment of cachexia faces substantial challenges, including the lack of FDA-approved therapies specifically for the condition, with agents like anamorelin approved only in regions such as Japan. Common side effects, such as edema, hyperglycemia, and cardiovascular risks, further complicate adoption, necessitating personalized risk-benefit assessments.^[46]

Epidemiology and History

Prevalence and Distribution

Cachexia affects millions of individuals worldwide each year, primarily as a complication of chronic diseases such as cancer, chronic heart failure (CHF), and chronic obstructive pulmonary disease (COPD). Globally, it contributes to approximately 2 million deaths annually, underscoring its significant burden on public health. In cancer patients, the prevalence ranges from 11% to 80%, depending on disease stage and type, with advanced cases often exceeding 50%; a 2024 meta-analysis reported an overall prevalence of 33.0% (95% CI, 32.8-33.3).^[4]^[25]^[81]^[82] The distribution of cachexia shows notable demographic and geographic patterns. It is more prevalent in low- and middle-income countries, where infectious diseases like tuberculosis exacerbate wasting syndromes, potentially doubling rates compared to high-income regions due to higher burdens of malnutrition and comorbidities. Among older adults, particularly those over 70 years, the incidence rises significantly, reaching up to 30% to 50% in patients with underlying chronic conditions such as cancer or heart failure, driven by age-related muscle loss and multimorbidity. Gender differences are less pronounced, though some studies indicate slightly higher rates in males for certain diseases like COPD.^[83]^[84]^[9] For CHF, cachexia occurs in 10% to 40% of patients, with recent estimates around 31%, while in COPD, estimates vary from 10% to 40%, particularly in severe emphysema phenotypes.^[5] Cachexia substantially elevates mortality risk, often doubling it in affected individuals with chronic diseases, independent of disease severity. In refractory cachexia, particularly in advanced cancer, 1-year survival rates can drop to around 20% to 30%, reflecting irreversible metabolic derangements and treatment intolerance. Emerging trends indicate an increasing prevalence, with hospital-based diagnoses rising from 1.2% to 1.9% between 2004 and 2019, largely attributable to aging populations; projections suggest a 67% increase in cancer-related cases among adults over 65 by 2030, amplifying the overall burden.^[85]^[86]

Historical Development

The recognition of cachexia traces back to ancient Greece, where Hippocrates (c. 460–370 BCE) first described it as a wasting condition in phthisis—now understood as tuberculosis—in which "the flesh is consumed and becomes water," the abdomen fills with water, and the feet and legs swell.^[9] This early account highlighted cachexia as a hallmark of progressive disease, distinguishing it from simple starvation through its association with fluid imbalances and emaciation.^[87] During the 19th century, cachexia gained wider medical attention as a feature of chronic illnesses, particularly tuberculosis, leading to the establishment of sanatoriums focused on supportive care to mitigate wasting.^[25] By the late 19th and early 20th centuries, it was increasingly linked to cancer, with clinicians observing involuntary weight loss, anorexia, and muscle depletion as common in advanced malignancies, often termed "cancer cachexia" to denote its tumor-specific nature.^[88] Pioneering metabolic studies in the 1930s, including Otto Warburg's elucidation of the "Warburg effect"—wherein tumor cells preferentially ferment glucose to lactate even in oxygen-rich environments—began to explain how cancers could induce host catabolism and energy diversion, contributing to cachectic states.^[89] In the modern era, understanding shifted from descriptive wasting to a formalized syndrome model. The 2008 European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines defined cachexia as a complex metabolic syndrome tied to underlying illness, characterized by loss of muscle mass with or without fat mass loss, emphasizing its multifactorial pathophysiology beyond mere malnutrition.^[90] Building on this, in 2011, Kenneth C. H. Fearon and an international consensus group proposed diagnostic criteria and staging for cancer cachexia, including precachexia (early metabolic changes), cachexia (weight loss >5% or >2% with low BMI/sarcopenia), and refractory cachexia (end-stage with treatment limitations), facilitating targeted clinical assessment.^[54] These developments underscored cachexia's progression and prognostic significance, influencing contemporary management approaches.

Research Directions

Current Studies

Phase III trials of anamorelin, a ghrelin receptor agonist (ROMANA 1 and 2, conducted 2014-2015), demonstrated significant gains in lean body mass and appetite improvement in patients with advanced non-small cell lung cancer and cachexia, though no overall survival benefit was observed compared to placebo. A 2025 post-hoc analysis confirmed these findings in subgroups with low BMI.^[91]^[92]^[93] Similarly, earlier trials with anti-TNF agents such as infliximab failed to show meaningful improvements in body weight or muscle function in cancer cachexia patients, highlighting limitations in targeting TNF-α alone.^[94]^[95] In 2024-2025 updates, preclinical research on gene therapy targeting myostatin has indicated potential for preserving skeletal muscle mass in cachexia models by inhibiting this negative regulator of muscle growth, with ongoing efforts to translate these findings to clinical applications.^[96]^[97] Additionally, studies on microbiome modulation have explored interventions to address gut-derived inflammation, such as increasing short-chain fatty acid-producing bacteria, which correlated with reduced muscle atrophy and improved metabolic profiles in murine cachexia models.^[98]^[99] Addressing gaps in multimodal therapy, a 2025 AI-driven predictive model using biomarkers from clinical, radiologic, and laboratory data achieved up to 85% accuracy in early detection of cachexia progression across cancer types, enabling potential tailored interventions.^[100] Analyses of clinical trials from 1995-2024 indicate that multimodal approaches (combining nutritional, exercise, and pharmacological interventions) represent about 9% of studies, with some showing benefits in stabilizing weight and quality of life, underscoring the need for further validation in larger cohorts.^[102]^[103]

Future Therapeutic Approaches

Emerging therapeutic targets for cachexia include inhibitors of myostatin signaling pathways, which promote muscle catabolism. Bimagrumab, a monoclonal antibody targeting activin type II receptors, has demonstrated potential in phase II trials for related conditions involving muscle wasting, such as sarcopenic obesity, by increasing lean body mass by approximately 7% compared to 1% with placebo.^[104] In September 2024, phase II results for ponsegromab, Pfizer's anti-GDF-15 antibody, demonstrated preservation of lean body mass, improved physical function, and reduced fatigue in patients with cancer cachexia and elevated GDF-15 levels.^[105] Selective androgen receptor modulators (SARMs), such as enobosarm, represent another key target by selectively promoting anabolism in muscle and bone without widespread androgenic effects; phase III trials (POWER 1 and 2) in cancer patients with cachexia reported significant increases in lean body mass, though primary endpoints for physical function were not met.^[106] These agents aim to counteract the hypercatabolic state central to cachexia across etiologies like cancer and chronic diseases.^[107] Multimodal innovations are advancing personalized interventions for cachexia management. Integrated AI models are being explored to tailor therapies, such as virtual dietitian systems that provide customized nutritional plans based on patient data, potentially enhancing treatment adherence and outcomes in cachexia.^[108] Stem cell therapies, particularly mesenchymal stem cells, show preclinical promise for muscle regeneration by promoting fiber repair and reducing inflammation in cachectic models, with animal studies demonstrating improved skeletal muscle function post-injection.^[109] Combining these with pharmacological agents could address the multifactorial nature of cachexia, though human trials remain limited. Lessons from current studies underscore the need for such integrated approaches to boost efficacy.^[110] Challenges in advancing cachexia therapies include the requirement for large-scale phase IV trials to confirm long-term safety and efficacy, particularly in refractory cases unresponsive to standard care, such as non-cancer-related cachexia where evidence gaps persist.^[111] The outlook emphasizes developing therapies that target underlying mechanisms like inflammation and metabolic dysregulation across diverse patient populations.^[112] Preventive strategies focus on early screening in high-risk diseases, such as advanced cancers or chronic kidney disease, using tools like nutritional risk assessments to intervene before significant weight loss occurs. Guidelines recommend routine evaluation of body weight, BMI, and muscle mass at diagnosis to enable timely nutritional and pharmacological support, potentially mitigating cachexia progression.^[113]^[67]

References

[1]
Cachexia - StatPearls - NCBI Bookshelf - NIH
Cachexia is a complicated metabolic syndrome related to underlying illness and characterized by muscle mass loss with or without fat mass loss.
[2]
Cancer cachexia, mechanism and treatment - PMC - PubMed Central
Cancer cachexia is characterized by systemic inflammation, negative protein and energy balance, and an involuntary loss of lean body mass.
[3]
Cancer Cachexia: Definition, Staging, and Emerging Treatments
Cachexia is a multifactorial disease characterized by weight loss via skeletal muscle and adipose tissue loss, an imbalance in metabolic regulation, and reduced ...
[4]
Prevalence of and Survival with Cachexia among Patients with Cancer
Aug 8, 2024 · The overall prevalence of cachexia in patients with cancer was 33.0% (95% confidence interval [CI], 32.8-33.3); however, it varied according to the definitive ...
[5]
Prognostic Impact and Prevalence of Cachexia in Patients ... - PubMed
Oct 30, 2024 · Conclusions: Cachexia is an independent predictor for increased all-cause mortality among patients with HF with a notable prevalence of 31%.
[6]
Cachexia: a systemic consequence of progressive, unresolved ...
Cachexia, a systemic wasting condition, is considered a late consequence of diseases, including cancer, organ failure, or infections, and contributes to ...
[7]
Cancer cachexia: impact, mechanisms and emerging treatments
Cachexia is generally defined as being involuntary weight loss of >5 % from historical weight, a body mass index (BMI) <20 kg/m2 with any degree of weight loss > ...<|control11|><|separator|>
[8]
Cancer cachexia: Pathophysiology and association with cancer ...
Aug 22, 2022 · Cachexia causes severe weakness and fatigue and negatively impacts quality and length of life. The negative energy balance in cachectic patients ...
[9]
Cancer Cachexia: New Insights and Future Directions - PMC
Nov 26, 2023 · Cachexia was defined as chronic disease-related malnutrition with associated inflammatory changes. The diagnostic criteria involved one ...Missing: symptoms | Show results with:symptoms
[10]
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines
Cachexia treatment requires a multimodal approach aimed at relieving symptoms impacting on food intake, ensuring adequate energy and nutrient intake, ...
[11]
Anorexia and Cachexia - StatPearls - NCBI Bookshelf
Jan 19, 2025 · The pharmacologic management of cachexia involves various medications that stimulate appetite, preserve muscle, and reduce inflammation and ...
[12]
Updates in Cancer Cachexia: Clinical Management and ...
Apr 27, 2024 · This narrative review provides an update on non-pharmacologic and pharmacologic treatment and proposes a theoretical model for management of CC.<|control11|><|separator|>
[13]
Cancer Cachexia: Beyond Weight Loss | JCO Oncology Practice
Sep 20, 2016 · Cancer cachexia has marked effects on QoL, physical function, and mortality. One reason for these effects may be related to the increased ...
[14]
Prevalence, incidence and clinical impact of cachexia
Nov 11, 2014 · Mortality rates of patients with cachexia range from 10 to 15 % per year in COPD through 20–30 % per year in chronic HF and CKD to 80 % in ...
[15]
Cachexia: pathophysiology and clinical relevance1,2 - ScienceDirect
Systemic inflammation mediated through cell injury or activation of the immune system triggers an acute inflammatory response that causes excess cytokine ...
[16]
Diverging metabolic programmes and behaviours during states of ...
Oct 28, 2020 · Unlike starvation and protein malnutrition, which are dictated by environmental nutrient availability, cachexia results from internal factors ...
[17]
The Nutritional Challenges of Cancer Cachexia - PMC - NIH
Cachexia is metabolically distinct from starvation or protein malnutrition, though many patients with cancer and cachexia exhibit lowered appetite and food ...Missing: hypermetabolism | Show results with:hypermetabolism
[18]
Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and ...
Weight loss due to an underlying disease is called cachexia and it usually involves a loss of fat and muscle mass. This review reflects on the similarities and ...
[19]
Skeletal muscle wasting in cachexia and sarcopenia - PubMed Central
Sarcopenia is characterized by the slow and progressive loss of muscle mass that is associated with ageing in the absence of any underlying disease or condition ...
[20]
Validated screening tools for the assessment of cachexia ...
There is great overlap between the presentation of cachexia, sarcopenia, and malnutrition. Distinguishing between these conditions would allow for better ...
[21]
Sarcopenia: European consensus on definition and diagnosis
Apr 13, 2010 · Sarcopenia is a syndrome characterised by progressive and generalised loss of skeletal muscle mass and strength with a risk of adverse outcomes ...
[22]
Cancer cachexia and its pathophysiology: links with sarcopenia ...
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass, along with adipose tissue wasting, systemic ...
[23]
Cachexia: A systemic consequence of progressive, unresolved ...
Apr 27, 2023 · With an estimated annual death rate of 2 million people worldwide, cachexia is one of the main contributors to human morbidity and mortality.
[24]
Cachexia in Pancreatic Cancer: New Insights to Impact Quality of ...
Cancer cachexia affects over 80% of pancreatic cancer patients, the highest rate among all malignancies [14], and negatively impacts quality of life and reduces ...Cachexia In Pancreatic... · 7.2. Nutritional... · 8. Future Directions And...<|control11|><|separator|>
[25]
Understanding cachexia and its impact on lung cancer and beyond
However, cancer cachexia not only has a dramatic impact on patients' quality of life but also increases the risk of treatment-related toxicity. Patients ...
[26]
Cachexia as a major public health problem: frequent, costly, and ...
Mar 29, 2013 · Cancer, 28–57. Chronic heart failure, 16–42. Chronic kidney disease, 30–60. COPD, 27–35. Rheumatoid arthritis, 18–67. HIV/AIDS, 10–35. Modified ...Missing: underlying | Show results with:underlying
[27]
The Prevalence and Prognosis of Cachexia in Patients with Non ...
Sep 1, 2024 · The prevalence of cachexia ranged from 3.4% to 66.2% in non-cancer patients and from 6.2% to 93% in cancer patients, which is consistent with ...
[28]
https://onlinelibrary.wiley.com/doi/10.1007/s13539-013-0105-y
[29]
Cachexia (Wasting Syndrome): Symptoms & Treatment
Apr 15, 2024 · For example, this condition accounts for 20% of all cancer-related deaths. ... of the chronic diseases that leads to cachexia. They may do tests ...
[30]
Polypharmacy is associated with malnutrition and activities of daily ...
Aug 27, 2021 · Polypharmacy influences malnutrition and activities of daily living (ADL) in older individuals owing to side effects such as anorexia.
[31]
A Pound of Flesh: What Cachexia Is and What It Is Not - PMC
Cachexia is a multifactorial syndrome characterized by body weight loss, declining muscle mass and function, wasting, and inflammation of adipose tissues ...
[32]
Frailty, Sarcopenia, Cachexia, and Malnutrition in Heart Failure - NIH
This review article provides an overview of the epidemiology, diagnostic methods, overlap, and prognosis of frailty, sarcopenia, cachexia, and malnutrition ...
[33]
The barriers to interprofessional care for cancer cachexia among ...
Nov 28, 2023 · Environmental factors. Necessity of reimbursement, Strongly agree or ... environmental barriers, including reimbursement availability, would ...Barriers In Personal... · Screening For Weight Loss · Barriers In Team Practice
[34]
Update on the Etiology, Assessment, and Management of COPD ...
Nov 18, 2022 · Smoking – Chief among the modifiable risk factors for COPD cachexia is continued tobacco smoking. Even among adults without COPD, longitudinal ...
[35]
Pathogenesis of Muscle Wasting in Cancer Cachexia
Cytokines such as TNF-α trigger degradatory pathways through NF-κB signaling that activate the ubiquitin-proteasome system and muscle proteolysis. Androgen ...
[36]
The role of interleukin‐6 family cytokines in cancer cachexia - Agca
Jul 8, 2024 · It is characterized by a rapid loss of adipose and skeletal muscle tissues, which is partly mediated by inflammatory cytokines. Here, we ...Introduction · Interleukin-6 family cytokines... · Interleukin-6 · Conclusion
[37]
https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.17224
[38]
Research progress on the mechanism and treatment of cachexia ...
Furthermore, TNF-α activates the ubiquitin-proteasome pathway through the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), ...
[39]
Tumor necrosis factor-α and muscle wasting: a cellular perspective
Experimental animals lose muscle mass when treated with TNF-α [2,3] or exposed to interventions that elevate endogenous TNF-α (e.g. sepsis or tumor implantation) ...Missing: percentage | Show results with:percentage
[40]
Inflammation and Skeletal Muscle Wasting During Cachexia - Frontiers
Increased levels of systemic inflammatory cytokines may result from spill over from an inflamed site, as is the cause for pulmonary inflammation. Ceelen et al.Abstract · Cachexia in Cancer and... · Indirect Effects of Inflammation
[41]
Molecular Mechanisms of Cachexia: A Review - MDPI
Systemic inflammation, driven by cytokines such as TNF-a, IL-6 and IFN-γ, plays an important role in the initiation and progression of muscle wasting. These ...2. Pathophysiology · 3. Biomarkers And Prognostic... · 4.1. Muscle Atrophy
[42]
Hypermetabolism and symptom burden in advanced cancer patients ...
Hypermetabolism, elevated resting energy expenditure (REE) > 110% of predicted REE, is characterized by an increase in the body's basal metabolic rate and ...
[43]
Cachexia: a problem of energetic inefficiency - PMC - PubMed Central
At present, it is widely held that elevated resting energy expenditure (REE) is a major determinant in the development of malnutrition in cachectic patients [13] ...Molecular Mechanisms Leading... · Oxidative Phosphorylation... · Metabolic Futile Cycles
[44]
Molecular Pathways Leading to Cancer Cachexia
Another futile cycle that may account for an energy loss of 300 kcal/day in cancer patients is the. Cori cycle (18). Tumors consume large amounts of glucose and ...
[45]
Current Therapeutic Targets in Cancer Cachexia - ASCO Publications
Jun 8, 2023 · Increasing evidence highlights the role of the CNS in the pathophysiology of cancer cachexia including hypothalamic inflammation, neuroendocrine ...
[46]
Cancer-Mediated Muscle Cachexia: Etiology and Clinical ...
Muscle cachexia has a major detrimental impact on cancer patients, being responsible for 30% of all cancer deaths.
[47]
IGF-1 Is Downregulated in Experimental Cancer Cachexia - PubMed
IGF-1 mRNA expression in the gastrocnemius of tumor hosts progressively decreases to approximately 50% of controls. By contrast, both IGF-1 receptor and insulin ...
[48]
Cancer cachexia: molecular mechanisms and treatment strategies
May 22, 2023 · According to many studies, ghrelin is known to suppress inflammation by releasing the anti-inflammatory cytokine IL-10 [44], which reduced the ...
[49]
Plasma Ghrelin Levels Are Associated with Anorexia but ... - Frontiers
As cachexia may be accompanied by a loss of appetite (anorexia) and ghrelin is directly involved in the regulation of hunger and appetite, it is ...
[50]
Cancer cachexia: Measured and predicted resting energy ...
Elevated resting energy expenditure (REE) may be a major determinant in the development of cancer cachexia. The aim of the study was to evaluate REE and body ...
[51]
Resting energy expenditure in the risk assessment of anticancer ...
Increased resting energy expenditure (REE) is frequent in cancer patients and may contribute to cachexia. ... Based on the ratio of measured REE to REE predicted ...
[52]
Understanding cachexia as a cancer metabolism syndrome - Nature
Feb 22, 2016 · Altogether, these data indicate that liver directly contributes to cachexia by promoting hypermetabolism and increased energy expenditure.
[53]
Definition and classification of cancer cachexia - PubMed
Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass)
[54]
Definition of cancer cachexia: effect of weight loss, reduced food ...
Conventional definitions of clinically significant weight loss usually use >10% as a cutoff (12). Recent data have suggested that in weight-losing patients with ...Subjects And Methods · Results · Discussion<|control11|><|separator|>
[55]
Measuring cachexia—diagnostic criteria - Dev
Both sarcopenia and sarcopenic obesity can be difficult to measure since no clear-cut consensus-based diagnostic criteria have been universally accepted and ...Introduction · Defining cancer cachexia · Assessment of cancer cachexia
[56]
RESULTS - Classification of Cancer Cachexia: A Systematic Review
Total CSS score ranges from 0-12, which is used to classify patients as noncachectic (0-2), precachexia (3-4), cachexia (5-8), or refractory cachexia (9-12).<|control11|><|separator|>
[57]
Hand grip strength in patients with advanced cancer - NIH
Jun 15, 2023 · Hand grip strength (HGS) is a widely used functional test for the assessment of strength and functional status in patients with cancer, ...
[58]
Hand grip strength‐based cachexia index as a predictor of cancer ...
Nov 29, 2022 · The cachexia index is a useful predictor for cancer cachexia and prognostic assessment. However, its use is limited because of high testing ...
[59]
Systemic Inflammation in Cachexia – Is Tumor Cytokine Expression ...
The cachectic patients in the study, beyond presenting severe weight loss in the previous 6 months, exhibited systemic inflammation and anemia (CRP >5.0 mg/L, ...
[60]
Emerging markers of cancer cachexia and their relationship to ...
Oct 31, 2023 · Significant relationships and differences of haemoglobin, CRP and albumin supports future use of these biomarkers in cancer cachexia.
[61]
Cancer cachexia: a nutritional or a systemic inflammatory syndrome?
May 6, 2022 · Conversely, a drop in serum albumin is also observed with rising CRP [7]. ... cytokines such as IL-1, TNF alpha and IL-6. 2. Treatment of patients ...
[62]
Relationships of emerging biomarkers of cancer cachexia with ...
May 14, 2024 · Albumin, NLR, Hb, PLR, SII, TNFα, IL-8, and CRP were reliable indicators of QoL, appetite, and cachexia.
[63]
Imaging modalities for diagnosis and monitoring of cancer cachexia
Sep 23, 2021 · MRI and CT are currently considered the gold standard imaging modalities to assess muscle mass [45]. However, earlier cancer cachexia studies ...
[64]
Body weight and composition endpoints in cancer cachexia clinical ...
May 13, 2024 · Computed tomography (CT) and magnetic resonance imaging (MRI) scans are considered the 'gold-standard' assessment modalities for body ...
[65]
Measurement of body mass by bioelectrical impedance analysis
Dec 11, 2020 · Approved direct methods include dual energy x-ray absorptiometry (DXA), computed tomography (CT), and magnetic resonance imaging (MRI). DXA ...
[66]
Bridging gaps in cancer cachexia Care: Current insights and future ...
CT imaging for body composition assessment is promising, but lengthy analysis, radiation exposure, machine accessibility, and high costs limit its application.
[67]
Biomarkers for Cancer Cachexia: A Mini Review - PMC - NIH
Apr 26, 2021 · Current diagnostic criteria for cancer cachexia are primarily based on loss of body mass and muscle function. However, these criteria are rather ...
[68]
[PDF] ESPEN practical guideline: Clinical Nutrition in cancer
NSAIDs may improve weight in cancer patients with cachexia, and there is some evidence of their effect on physical performance, self-reported quality of life, ...
[69]
[PDF] ESPEN guidelines on nutrition in cancer patients
2: Muscle protein depletion is a hallmark of cancer cachexia, severely impinging quality of life and negatively impacting physical function and treatment ...
[70]
[PDF] ESPEN expert group recommendations for action against cancer ...
The burden of cachexia can be lowered or alleviated by comprehensive nutrition care tailored to meet the needs of the patient during different stages of the ...<|control11|><|separator|>
[71]
Exercise Training as Therapeutic Approach in Cancer Cachexia
↓Body weight ↓Functional capacity, Progressive resistance training, 13 training sessions, 3 times weekly for 30 min, 3 exercises for major muscle groups with 8– ...Table 1 · Exercise And Tumoral... · Physical Exercise And...<|separator|>
[72]
A randomized phase II feasibility trial of a multimodal intervention for ...
Jun 14, 2017 · It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. The primary aim of this study was to examine ...
[73]
Management of Cancer Cachexia: ASCO Guideline
May 20, 2020 · In 2009, the Italian research group SCRINIO defined cancer-specific cachexia as weight loss > 10% with symptoms of anorexia, early satiety, and ...
[74]
Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines
Apr 29, 2021 · Regular nutritional screening and nutritional support, including (if necessary) enteral nutrition or PN, is recommended in all patients ...
[75]
Tocilizumab for Advanced Non-Small-Cell Lung Cancer ... - PubMed
Nov 11, 2024 · This study aimed to investigate the use of tocilizumab in the management of NSCLC with coexisting IL-6-elevated cachexia.Missing: inhibition | Show results with:inhibition
[76]
Update on clinical trials of growth factors and anabolic steroids in ...
Oxandrolone, a modified testosterone derivative with minimal androgenic effects, has been approved for several decades as an oral anabolic agent for both men ...
[77]
Anamorelin in patients with non-small-cell lung cancer and cachexia ...
Feb 19, 2016 · Anamorelin significantly increased lean body mass, but not handgrip, strength in patients with advanced non-small-cell lung cancer. Considering ...
[78]
A Critical Review of Multimodal Interventions for Cachexia
Apr 26, 2020 · Reflective of the complexity of the syndrome of cachexia, recent trials have adopted multimodal interventions (3, 30) consistent with scientific ...
[79]
Prevalence and clinical impact of cachexia in chronic illness in ... - NIH
Its prevalence ranges from 5–15% in end‐stage chronic heart failure to 50–80% in advanced malignant cancer. Cachexia is also frequently occurring in patients ...Missing: global | Show results with:global
[80]
Prevalence, incidence and clinical impact of cachexia - NIH
Cachexia is a serious but underrecognised consequence of many chronic diseases. Its prevalence is 5–15 % in end-stage chronic heart failure (HF) and it forms ...Missing: infections HIV tuberculosis
[81]
Cachexia as a major public health problem: frequent, costly, and ...
Mar 29, 2013 · Cachexia increases mortality in chronic disease and is present in about 30 % of patients that die. Annual mortality rates are disease dependent: ...
[82]
Prevalence and prognostic impact of cachexia among older patients ...
More than half of older patients with cancer managed in geriatric oncology clinics had cachexia. The factors associated with cachexia were upper ...<|control11|><|separator|>
[83]
Prevalence of Cachexia and Outcomes in Patients With Chronic ...
Jan 20, 2025 · From 2004 to 2019, prevalence of cachexia increased steadily from 1.2% to 1.9%, which was most prominent for cancer and chronic obstructive pulmonary disease.
[84]
Cachexia and Sarcopenia in Older Adults with Cancer - MDPI
Cancer cachexia, diagnosed by an examination of weight loss, body mass index (BMI) and skeletal muscle, is very common in older adults with cancer. Among ...
[85]
Ponsegromab for Cancer Cachexia — A New Dawn for an Old ...
Dec 18, 2024 · Hippocrates, the father of medicine (460 to 370 b.c.), described cachexia as a condition in which “the flesh is consumed and becomes water ...Missing: modern era
[86]
What is cancer anorexia-cachexia syndrome? A historical perspective
In cancer cachexia, most historical descriptions included anorexia, wasting and a pale complexion. Other associated symptoms, such as fatigue, early satiety ...
[87]
The Warburg effect: 80 years on - PMC - NIH
Oct 19, 2016 · Otto Warburg first described in the 1920s that cancer cells utilised higher levels of glucose in the presence of oxygen with an associated ...The Warburg Effect · Cancer Hallmarks And... · Positron Emission Tomography...
[88]
Cachexia: a new definition - PubMed
Cachexia is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass.
[89]
Phase III trials of anamorelin in patients with advanced non-small ...
May 20, 2015 · Anamorelin increased lean body mass, body weight, total body mass and fat mass indicating anabolic activity and restoration of energy balance in patients with ...
[90]
Anamorelin in the Management of Cancer Cachexia
In several randomized, double-blind, placebo-controlled clinical trials, anamorelin significantly improved lean body mass and appetite in patients with cancer ...
[91]
Randomized phase 2 trial of anti-tumor necrosis factor therapy for ...
However, little evidence shows that anti-TNF therapy is effective in treating cachexia in humans.
[92]
Anti-cytokines in the treatment of cancer cachexia - Prado
In preclinical studies, for example, IL-1, TNF-alpha, and IL-6 have been linked to the development of weight loss, skeletal muscle catabolism, and adipose ...Pathogenesis Of Crc And The... · Anti-Cytokine Agents For... · Thalidomide
[93]
A molecular pathway for cancer cachexia-induced muscle atrophy ...
Aug 27, 2024 · Our findings show that a denervation-dependent gene program upregulates the expression of myogenin and its target gene myostatin, thereby ...
[94]
Targeting myostatin in cancer cachexia: Exploring the potential of ...
Jun 2, 2025 · Penumarthi, Krish. 2025. “Targeting Myostatin in Cancer Cachexia: Exploring the Potential of MSTN Gene Therapy.” Scholarly Review Journal Summer ...Missing: 2024-2025 | Show results with:2024-2025
[95]
Modulating the Gut–Muscle Axis: Increasing SCFA-Producing Gut ...
Jun 11, 2025 · Studies in both murine models and humans consistently associate cachexia with a decline in SCFA-producing gut microbiota commensals and an overgrowth of pro- ...
[96]
Targeting Gut Microbiota in Cancer Cachexia: Towards New ... - MDPI
A number of studies have shown alterations in gut microbiota diversity and composition in association with cancer cachexia markers and symptoms.
[97]
AI-driven Biomarker Model May Improve Detection of Cancer ...
Apr 27, 2025 · “Compared with traditional biomarkers, AI-driven biomarkers may enable more sensitive and accurate detection of cancer cachexia by uncovering ...
[98]
Multimodal AI-driven Biomarker for Early Detection of Cancer ...
Sep 19, 2025 · This work advances a clinically applicable, scalable, and trustworthy AI-driven decision support tool for early cachexia detection and ...
[99]
Landscape of Clinical Trials in Cancer Cachexia - NIH
Mar 16, 2025 · In this retrospective review, we evaluated the landscape of clinical trials registered on ClinicalTrials.gov for the consideration of potential factors ...
[100]
Landscape of clinical trials in cancer cachexia: assessment of trends ...
Aug 4, 2025 · Moreover, five trials (9.6%) were classified under “sarcopenia”, nine trials (17.3%) were classified under “weight loss”, four trials (7.7%) ...
[101]
Bimagrumab vs Optimized Standard of Care for Treatment of ...
Oct 19, 2020 · Bimagrumab was safe and well-tolerated and increased lean body mass by 7% (95% CI, 6% to 8%) vs 1% (95% CI, 0% to 2%) with placebo, resulting in ...
[102]
Therapeutic applications and challenges in myostatin inhibition for ...
Sep 28, 2024 · Landogrozumab was tested in phase 2 trials targeting sarcopenia, sarcopenia related to hip surgery, and cachexia. Following 5 equally spaced ...
[103]
Effects of enobosarm on muscle wasting and physical function in ...
Interpretation. Cancer cachexia is an unmet medical need and our data suggest that use of enobosarm might lead to improvements in lean body mass, without the ...
[104]
potential anabolic drugs for the treatment of cachexia and frailty ...
Jun 13, 2025 · Sarms are a relatively new group of substances that could be used in the future to improve the condition of patients with cachexia and frailty syndrome.
[105]
Artificial intelligence in cancer-related malnutrition and cachexia - NIH
... Cachexia and Treatment-responsive Cachexia With AI ... AI-driven virtual dietitian systems designed to support patients with personalized nutritional therapy.
[106]
Restoration of skeletal muscle function via mesenchymal stem cells
Preclinical studies have demonstrated that the local injection of mesenchymal stem cells (MSCs) significantly promotes the regeneration of muscle fibers in ...Mesenchymal stem cell (MSCs) · MSCs and skeletal muscle · Myasthenia gravis
[107]
Stem Cells for Skeletal Muscle Regeneration: Therapeutic Potential ...
Conditions involving muscle wasting, such as muscular dystrophies, cachexia, and sarcopenia, would benefit from approaches that promote skeletal muscle ...
[108]
New models for cancer cachexia and their application to drug ...
GDF-15 and GLP-1 have emerged from recent experimental studies as pivotal therapeutic targets for alleviating anorexia associated with cancer cachexia, ...2.1. Orthotopic... · 5.1. Gdf-15 And Anorexia · 5.2. Glp-1 And Anorexia<|control11|><|separator|>
[109]
Advancing the Understanding and Treatment of Cancer Cachexia
Oct 11, 2025 · In the clinical treatment of tumor cachexia, it has been clearly defined that there are multiple methods available for treating this disease, ...
[110]
Guidelines for clinical diagnosis and treatment of cancer cachexia
For clinical convenience, cachexia diagnosis is primarily based on the presence of underlying disease, anorexia, progressive weight loss, and inflammation. The ...